Novo Nordisk has made its smart insulin pens available in the UK, giving people treated within the NHS for diabetes access to devices that can monitor and record dosing information for the first time.

“To address our current capacity constraints and reach more people with diabetes with our products in the future, our human insulin, which is currently delivered in pens and vials, will—over ...

Insulin as part (rDNA origin) injection Novolog (Novo Nordisk) 28 days Prescribing information Insulin glargine (rDNA origin) vial or cartridge Lantus vial or cartridge (Sanofi-Aventis) 28 days ...

LONDON (Reuters) -Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp up manufacturing of its popular obesity and diabetes ...

30 days Prescribing information Regular human insulin injection (rDNA origin) Novolin R vial (Novo Nordisk) 30 days Prescribing information Humulin Ultralente human insulin (rDNA origin ...

Novo Nordisk is gradually ceasing the production of its human insulin pens, according to announcements made by the company. As it pivots towards manufacturing its newer obesity and diabetes injections ...

Novo Nordisk, in a strategic shift, is set to phase out the production of human insulin pens globally, although it remains unclear when this will occur. The pharmaceutical giant is redirecting its ...

The companion app for the InPen digital insulin pen is designed to connect with the company’s latest Simplera continuous glucose monitor, offering users personalized dosing suggestions based on ...

The medical device manufacturer Owen Mumford has announced that it will stop producing its Autopen range of insulin delivery pens. Here, we look at what this means for people with diabetes who might ...

They are calling for the Danish multinational to withdraw its decision to discontinue its provision of human insulin pens “in South Africa and other developing countries”. MSF also wants the ...